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Abstract
Background: Little is known about the prevalence and clinical importance of potentially inappropriate prescribing
instances (PIPs) in the very old (>80 years). The main objective was to describe the prevalence of PIPs according to
START (Screening Tool to Alert doctors to Right Treatment; omissions) and,STOPP (Screening Tool of Older Person’s
Prescriptions; over/misuse) and the Beers list (over/misuse). Secondary objectives were to identify determinants if
PIPs and to assess the clinical importance to modify the treatment in case of PIPs.
Methods: Cross-sectional analysis of baseline data of the BELFRAIL cohort, which included 567 Belgian patients
aged 80 and older in primary care. Two independent researchers applied the screening tools to the study
population to detect PIPs. Next, a multidisciplinary panel of experts rated the clinical importance of the PIPs on
a subsample of 50 patients.
Results: In this very old population (median age 84 years, 63 % female), the screening detected START-PIPs in
59 % of patients, STOPP-PIPs in 41 % and Beers-PIPs in 32 %. Assessment of the clinical importance revealed that
the most frequent PIPs were of moderate or major importance. In 28 % of the subsample, the relevance of the PIP
was challenged by the global medical, functional and social background of the patient hence the validity of some
criteria was questioned.
Conclusion: Potentially inappropriate prescribing is highly prevalent in the very old. A good understanding of the
patients’ medical, functional and social context is crucial to assess the actual appropriateness of drug treatment.
Keywords: Inappropriate Prescribing, Aged 80 and older, Primary care, General practice, STOPP&START, Beers
Background
Potentially inappropriate prescribing (PIP) is highly
prevalent in older adults and has been associated with
adverse drug events, hospitalization and death [1–4]. A
review reported that the median rate of inappropriate
prescribing in primary care was around 20 % in patients
aged over 65 years old [5]. But little is known about the
prevalence of inappropriate prescribing in the very old,
yet the latter represent a challenge for healthcare, be-
cause of multiple comorbidities, polypharmacy, frailty
features and increased sensitivity to adverse drug events.
Several approaches exist to detect and reduce the bur-
den of inappropriate prescribing in elderly, including the
use of criterion-based screening tools, also called explicit
tools [2, 6]. The most studied explicit tool is the Beers
list, which was first published in 1991 [7] and last up-
dated in 2012 [8]. In recent years, another explicit tool,
the Screening Tool of Older Person’s Prescriptions
(STOPP) and Screening Tool to Alert doctors to Right
Treatment (START) [9], has been increasingly used [1].
The tool aims at detecting PIP in patients aged over
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65 years old, which was the population target of most of
the published studies using this tool. While Beers and
STOPP address over- and misuse of inappropriate medi-
cations, the START tool allows for the detection of po-
tentially inappropriate drug omissions. Some overlap of
content between the STOPP and the 2012 Beers criteria
has been described [10–13]. In the very old, to the best
of our knowledge, no comparison with the updated 2012
Beers list has been performed. A recent study including
inpatients aged 85 years and over measured the preva-
lence of PIPs according to STOPP&START and to a pre-
vious version of the Beers criteria (2003) [13]. This study
showed a high prevalence of PIPs in that very old popu-
lation (STOPP: 63 %; START: 54 %, Beers: 47 %) [13].
Moreover, the actual clinical relevance of those tools in
the very old is unknown. Indeed, previous studies
showed that potentially inappropriate prescribing de-
tected by screening tools might differ from actually in-
appropriate prescribing [14–16].
The primary objective of this study was to determine
the prevalence of PIP in community-dwelling patients
aged 80 and older (the BELFRAIL population) [17] ac-
cording to START (START-PIP), STOPP (STOPP-PIP)
and Beers (Beers-PIP) tools.
Secondary objectives included the identification of de-
terminants of PIPs in this population, and assessment of
the clinical importance of a subsample of PIPs.
Methods
Study design, setting and participants
We performed a cross-sectional analysis of the baseline
data of the BELFRAIL cohort (BFC80+) [17]. The BELF-
RAIL study is a prospective, observational, population-
based cohort study of Belgian subjects aged 80 years and
older [17]. The subjects were recruited in Belgium by
their general practitioners (GPs) between November 2,
2008 and September 15, 2009, as described elsewhere
[17]. This cohort excluded patients with severe dementia
(mini mental state examination [18] MMSE <15/30),
treated in palliative care and or as medical emergency.
The protocol of this study was approved by the Biomed-
ical Ethics Committee of the Medical School of the
Université catholique de Louvain (UCL) of Brussels,
Belgium (B40320084685). All patients gave written in-
formed consent. Because patients with severe dementia
(MMSE < 15) were excluded, all patients were able to
give the informed consent themselves.
Data collection
Medical and background data
For the 567 patients of the cohort, the GPs performed a
detailed medical history and clinical examination [17].
The GPs reported the complete problem list of their pa-
tients as free text. Additionally, a structured questionnaire
assessed the presence of 22 chronic conditions. Two re-
searchers coded independently all the comorbidities listed
by the GPs (OD and PB). Discrepancies were discussed
with a third researcher (BV) until a consensus was
reached. The Cumulative Illness Rating Scale (CIRS) was
calculated [19–21]. The CIRS counts the number of 14
body systems affected with moderate disability, morbidity
or extremely severe disease [19–21]. (Score varies from 0
to 14). Background data collection also included: cognitive
impairment measured by the MMSE (score <25 was con-
sidered as “cognitive impairment”) [18], geriatric de-
pression scale score GDS-15 (score >4 was considered
as “possible depression”) [22], Tinetti fall risk score
(score >24 was considered as “low fall risk”) [23], func-
tional status according to the activities of daily living
(ADL) score (ADL ranged between 6 and 30, lower
score is related to functional dependency) [24], incon-
tinence (reported by the GP), body mass index, familial
status, and place of residence.
Drugs and inappropriate prescribing
GPs were asked to list the drugs the patient was taking
on a regular basis or as needed. Drugs were coded and
classified according to the Anatomical Therapeutic
Chemical (ATC) classification system by one researcher
(MA) [25].
Two researchers (OD and AD) independently retro-
spectively applied the 87 criteria of the STOPP&START
tool [9] and the 3 categories of Beers’ criteria (drugs to
avoid, to avoid regarding certain conditions/diseases,
and to use with caution) [8] to the coded medical condi-
tions and drugs. Discrepancies were discussed until con-
sensus. For the analysis of the secondary outcomes, the
Beers drugs to use with caution were not considered.
Determinants of PIP
Potential determinants of PIPs were tested among the fol-
lowing variables: medical (CIRS categorized as <4, or =4,
or >4), geriatric (polypharmacy [≥5 drugs/day], MMSE
[>25 (no cognitive impairment) or 20–24 or <20], ADL
adjusted for gender [lowest quintile (higher dependence)
or higher quintiles], GDS-15 [< or ≥5 (possible depres-
sion)], Tinetti score [25–28 (lowest fall risk) or 19–24
or ≤18], incontinence, body mass index [< or ≥21 kg/m2]
[26, 27]) and social (age, gender, institutionalisation).
Clinical importance
On a randomly selected subsample of 50 patients, an ex-
pert panel (a general practitioner (JD), a geriatrician
(BB) and a clinical pharmacist (AS), all with research ex-
perience in the field) was asked to independently rate
the actual clinical importance of the recommendations
(i.e., to add the drugs suggested by START to the treat-
ment, or to discontinue the drugs detected by STOPP or
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Beers). Recommendations were classified following a
previously defined method as minor, moderate, major,
extreme, deleterious or not applicable (description of
classifications can be found in Table 4) [14, 28]. Consen-
sus on the clinical importance was reached when 2 ex-
perts agreed. To assess PIPs in the thorough context of
the patient, the panel had access to the full record pro-
vided by the GP, and not only the coded conditions.
Statistical analysis
Normally distributed continuous variables were expressed
as mean ± standard deviation, while not normally distrib-
uted ones were summarized using the median and the
inter-quartile range [Q25;Q75]. For categorical variables,
numbers and percentages were presented. A univariate
analysis and a multivariate logistic regression analysis were
used to identify determinants of potentially inappropri-
ate prescribing according to each tool. Variables with a
p value of <0.05 in the univariate analysis were submit-
ted for multivariate regression analysis. A p value <0.05
was considered statistically significant in the multivari-
ate analysis. Statistical analyses were performed using
IBM SPSS Statistics 20 (SPSS Inc., Chicago, IL, USA).
Results
The characteristics of the 567 patients included at base-
line in the cohort are presented in Table 1. Patients had
a median age of 84 years, 63 % were female and they
lived mainly at home (90 %). The most frequent comor-
bidities they presented were: hypertension (70 %), osteo-
arthritis (57 %) and ischemic disease (37 %). Eighty-one
percent of the patients had at least one PIP in their med-
ications: 59 % had START-PIPs (drug omissions), 41 %
had STOPP-PIPs and 32 % had Beers-PIPs (drug overuse
and/or misuse).
Inappropriate prescribing
Overall, we found 1.13 ± 1.34 START-PIP per patient;
range 0–8. In the 59 % of patients having at least one
START-PIP, the average of START-PIPs rose to 1.90 ±
1.25 per affected patient.
Table 1 Characteristics of the patients of the BELFRAIL cohort
(N = 567)
Characteristics of the patients
Age (years), median [Q25;Q75] 84.0 [81.7;86.6]
Gender, women, n (%) 356 (62.8)
Resident in a nursing home, n (%) 57 (10.1)
Number of drugs/day, median [Q25;Q75] 5 [4;7]
Geriatric features
Polypharmacy (≥ 5 drugs/day), n (%) 337 (61)
ADL,a median [Q25;Q75] 25 [21;27]
Living alone at home, n (%) 212 (37.4)
Urinary incontinence, n (%) 126 (22.2)
Cognitive impairement, n (%) 89 (15.7)
BMI < 21 kg/m², n (%) 49 (8.6)
MMSE,b median [Q25;Q75] 28 [25;29]
Tinetti score,c median [Q25;Q75] 27 [24;28]
GDS-15,d median [Q25;Q75] 2 [1;4]
CIRS median [Q25;Q75] 4 [3;5]
Most frequent comorbidities
Hypertension, n (%) 396 (69.8)
Osteoarthritis, n (%) 324 (57.1)
Ischemic disease, n (%) 210 (37.0)
Chronic heart failure, n (%) 166 (29.3)
Chronic renal disease (GFR < 50 ml/min), n (%) 143 (25.2)
Osteoporosis, n (%) 125 (22.0)
Diabetes, n (%) 107 (18.9)
Depression, n (%) 74 (13.1)
COPD, n (%) 65 (11.5)
Atrial fibrillation, n (%) 58 (10.2)
Most frequent drugs prescribed, n patients (%)
Antithrombotic agents (B01) 312 (55.0)
Beta-blocking agents (C07) 238 (42.0)
Agents acting on the renin-angiotensin system (C09) 237 (41.8)
Psycholeptics (N05) 220 (38.8)
Diuretics (C03) 189 (33.3)
Lipid Modifying Agents (C10) 180 (31.7)
Drugs for acid related disorders (A02) 138 (24.3)
Calcium Channel Blockers (C08) 135 (23.8)
Psychoanaleptics (N06) 131 (23.1)
Cardiac Therapy (C01) 115 (20.3)
Potentially inappropriate prescribing, n patients (%)
Table 1 Characteristics of the patients of the BELFRAIL cohort
(N = 567) (Continued)
START-PIPs 336 (59.3)
STOPP-PIPs 232 (40.9)
Beers-PIPs 180 (31.7)
Abbreviations: ADL activities of daily living, BMI body mass index, CIRS
cumulative illness rating scale, COPD chronic obstructive pulmonary disease,
GDS geriatric depression scale, GFR glomerular filtration rate, MMSE mini
mental state examination, PIPs potentially inappropriate prescribing
aADL ranged between 6 and 30, lower score is related to functional
dependency
bMMSE <25 was considered as “cognitive impairment”
cTinetti score >24 was considered as “low fall risk”
dGDS-15 score >4 was considered as “possible depression”
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Patients had on average 0.58 ± 0.92 STOPP-PIP in
their list of prescriptions; range 0–10. The 41 % of
affected patients had 1.43 ± 0.95 STOPP-PIP in their
treatment.
The application of the Beers tool pointed out
Beers-PIPs as drugs to avoid or to avoid in the pres-
ence of certain conditions in 32 % of the patients.
The mean number of Beers-PIP in the treatment was
0.44 ± 0.79 per patient; range 0–6. In patients having
at least one Beers-PIP, the average was 1.38 ± 0.80 per
affected patient. In addition, Beers drugs that are
labelled to be used with caution were found in 45 %
of the patients.
Overall, 108 patients out of the 567 (19 %) had no
PIP at all when considering START, STOPP and Beers
tools. The most frequent PIPs are presented in Table 2.
As far as underuse was concerned, the most frequent
drug category using START was cardio-vascular (anti-
platelet, statin, angiotensin-converting-enzyme inhi-
bitors). The most frequent drug categories related
to misuse or overuse were cardiovascular and psycho-
tropic drugs (aspirin, benzodiazepines) and similar
using STOPP and Beers. The prevalence of PIPs related
benzodiazepine use with history of falls was less than
1 % (one patient). However, 19 % of the patients on
benzodiazepines were at high fall risk according to
their Tinetti score, and could therefore be assimilated
to patients having PIPs.
Determinants of PIP
The results of the multivariate analysis are shown in
Table 3. A lower comorbidity score was a determinant
of lower odds of having START-PIPs (odds ratio [OR]
0.2, 95 % confidence interval [CI] 0.1–0.3 for CIRS <4
vs. >4). Functional dependence (lowest quintile of ADL,
range in women 6–18, range in men 6–21) was the only
determinant of having STOPP-PIP (OR 1.5, 95 % CI
1.0–2.4). Beers-PIPs were also associated with the CIRS
(OR 0.4, 95 % CI 0.3–0.7 for CIRS <4 vs. >4, and OR
0.6, 95 % CI 0.4–0.9 for CIRS =4 vs. >4). Living in a
nursing home was another determinant of Beers-PIPs
(OR 1.8, 95 % CI 1.0–3.4). Other social and geriatric
features were not related to PIPs.
Clinical importance of the recommendations to modify
the treatment in the presence of PIP
In the subsample of 50 patients, the experts examined 143
PIPs (i.e.,: 44 STOPP-PIPs, 65 START-PIPs and 34 Beers-
PIPs [including 3 PIPs overlapping the STOPP-PIPs], con-
cerning 17 different criteria of the START tool, 18 criteria
from STOPP and 20 criteria from Beers). The experts
Table 2 Most frequent potentially inappropriate prescribing events according to START, STOPP and/or Beers criteria
Therapeutic class/medication ± disease Prevalence % (n)
Under prescribing according to
START
Aspirin or clopidogrel with a documented history of atherosclerotic coronary, cerebral or
peripheral vascular disease in patients with sinus rhythm
15,0 (85)
Calcium and vitamin D supplement in patients in the presence of known osteoporosis 13,9 (79)
ACE inhibitor in the presence of chronic heart failure 12,7 (72)
Statin therapy with a documented history of coronary, cerebral or peripheral vascular
disease, where the patient’s functional status remains independent for activities of daily
living and life expectancy is greater than 5 years
9,5 (54)
Antiplatelet therapy in diabetes mellitus with coexisting major cardiovascular risk factors
(hypertension, hypercholesterolemia, smoking history)
9,5 (54)
Over/misprescribing according to
STOPP or/and Beers
STOPP and Beers Aspirin for primary cardiovascular preventiona 16,9 (96)
Beers Nonbenzodiazepine (“Z”) hypnotics (i.e., eszoplicone, zaleplon, zolpidem) 6,2 (35)
STOPP Any duplicate drug class prescription 6,2 (35)
Beers Benzodiazepines in the presence of dementia and cognitive impairment 5,8 (33)
STOPP and Beers Long-acting benzodiazepines 4,9 (28)
STOPP Aspirin at dose > 150 mg/day 4,4 (25)
STOPP NSAIDs with moderate to severe hypertension 3,7 (21)
Beers Tertiary TCAs, alone or in combination 2,6 (15)
Abbreviations: ACE angiotensin-converting-enzyme, NSAIDs nonsteroidal anti-inflammatory drugs, TCA tricyclic antidepressant
aTo be used with caution in adults >80 years old for primary prevention of cardiac events in Beers 2012; to be avoided in those with no history of coronary,
cerebral, or peripheral vascular symptoms or occlusive events in STOPP
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agreed on the clinical importance of 83 % of the PIPs. The
clinical importance of the same criterion could vary in
different patients according to each patient’s individual
context.
Forty-three PIPs cases (30 %) were rated of “major”
importance, while 33 PIPs (23 %) were considered of mod-
erate importance. The experts rated two PIPs as “minor”.
One START-PIP appeared to be “deleterious”. Examples
are provided in Table 4. Finally, the experts agreed that 40
PIPs (28 %) were “non-applicable” according to the indi-
vidual context and even considered 19 of those cases
(13 %) as actually appropriate prescribing.
The 40 “non applicable” cases could be divided into
two categories. The first category encompassed 25 cases
where the experts found nuances within the detailed full
record of the patient, including the comprehensive geri-
atric assessment, which questioned the applicability of
the criteria. In the second category (n = 15), the experts
questioned the content validity of the criteria. Examples
are provided in Table 5. Comparing the PIPs detected by
the three tools, START-PIPs were the most frequently
rated as “non applicable”.
Discussion
Summary
For the first time, this study described inappropriate pre-
scribing and their determinants in a large representative
sample of community-dwelling very old patients. In this
population, the prevalence of PIPs was high. Potentially
inappropriate omissions, detected by the START tool
were more prevalent (59 % of the patients) than overuse
of treatment (STOPP: 41 %; Beers’ drugs “to avoid”:
32 %). Drugs from the cardiovascular and neurologic
systems were the most frequently involved in PIPs.
Among medical, social and geriatric features, the CIRS
was related to having START- and Beers-PIPs, place of
residency was associated with Beers-PIPs and the func-
tional dependence was determinant of having STOPP-
PIPs.
The evaluation of the relevance of the criteria showed
that a holistic approach of the patient changed the ap-
plicability of the criteria in 17 % of PIP cases. More im-
portantly, in 10 % of cases, the recommendation to
modify the drug regimen was not valid, and could even
be considered as deleterious, which is not acceptable.
Finally, the experts did not rate similarly the clinical im-
portance of the criteria in 17 % of cases. This illustrates
the subjectivity of the assessment of the patient’s context
and the variable importance acknowledged to inappro-
priate prescribing according to the evaluator.
Comparison with existing literature
The prevalence detected in our patients aged 80 and
older (START : 59 %; STOPP: 41 %; Beers’ drugs “to
avoid”: 32 %) did not substantially differ from the preva-
lence reported in the literature with populations includ-
ing younger patients in whom the range of prevalence of
START-PIP is 23 to 68 % [29–32], STOPP-PIP 18-60 %
[30, 32–37], and Beers-PIP 12.5–42 % [38, 39]. This ob-
servation is consistent with a study published in 2015
that compared the prevalence of START-PIPs, STOPP-
PIPs and Beers-PIPs in patients aged between 75 and
84 years vs patients aged 85 and over, in the hospital set-
ting [13]. The prevalence of PIPs was similar in both
groups [13]. It should be noted that prevalence of PIPs
varies greatly from studies, depending of the setting and
the range of the criteria of the tools that were taken into
account.
Table 3 Determinants of potentially inappropriate prescribing
in the study population (multivariate analysis)
Covariates OR [95 % CI] p value
START-PIP
ADL lowest quintilea 0.8 [0.4–1.5] 0,523
Age, per year 1.0 [0.9–1.1] 0,227
CIRS >4 1.0
CIRS <4 0.2 [0.1–0.3] <0,001
CIRS=4 0.6 [0.3–1.1] 0,090
GDS-15 >4b 1.2 [0.7–2.0] 0,442
Gender, women 0.9 [0.6–1.4] 0,727
Tinetti ≤ 18c 1.0
Tinetti 25–28 0.5 [0.2–1.2] 0,130
Tinetti 19–24 0.9 [0.3–2.2] 0,840
STOPP-PIP
ADL lowest quintile 1.5 [1.0–2.4] 0.050
Age, per year 1.0 [0.9–1.0] 0.957
Gender, women 1.2 [0.9–1.8] 0.211
Resident in a nursing home 1.8 [0.9–3.2] 0.056
BEERS-PIP
ADL lowest quintile 1.1 [0.7–1.9] 0.558
Age, per year 0.9 [0.9–1.0] 0.515
CIRS >4 1.0
CIRS < 4 0.4 [0.3–0.7] <0.001
CIRS = 4 0.6 [0.4–0.9] 0.041
GDS-15 >4 1.5 [0.9–2.3] 0.094
Gender, women 1.2 [0.8–1.8] 0.364
Resident in a nursing home 1.8 [1.0–3.4] 0.045
Hosmer-Lemeshow goodness-of-fit P-value for START = 0.42; STOPP = 0.15;
Beers = 0.89 indicating that the models are a good fit for the data
Abbreviations: ADL activities of daily living, CI confidence interval, CIRS
cumulative illness rating scale, GDS geriatric depression scale, OR odds ratio,
PIPs potentially inappropriate prescribing
aADL lowest quintile: lower ADL score is related to functional dependency
bGDS-15 score >4 was considered as “possible depression”
cTinetti score >24 was considered as “low fall risk”; ≤ 18 was “high fall risk”
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Table 4 Clinical importance of potentially inappropriate
prescribing criteria according to the expert panel
Examples
Major
clinical
importance
(n = 43)
Modification of the
treatment according to
this criteria may
prevent serious
morbidity, including
readmission, serious
organ dysfunction,
serious adverse drug
event
Criterion: START-PIP
“Angiotensin
converting enzyme
(ACE) inhibitor with
chronic heart failure”.
Context: The GP
reports chronic heart
failure, with marked
limitation of physical
activity and dyspnea,
and a recent episode
of congestive heart
failure.
Criterion: STOPP-PIP
“Calcium channel
blockers with NYHA
class III or IV heart
failure”/Beers- PIP
“Diltiazem in heart
failure”.
Context: The medical
history and the clinical
examination confirm
that the patient has
NYHA class III heart
failure.
Criterion: Beers- PIP
“Anticholinergics in
dementia and
cognitive
impairment”.
Context: The patient
has cognitive
impairment (MMSE =
22/30a) and takes
several drugs with
anticholinergic
properties
(amisulpride,
trihexyfenidyl).
Moderate
clinical
importance
(n = 33)
Modification of the
treatment according to
this criteria brings care
to a more acceptable
and appropriate level
of practice or that may
prevent an adverse
drug event of
moderate importance
Criterion: START-PIP
“Statin therapy in
diabetes mellitus if
coexisting major
cardiovascular risk
factors present”.
Context: The patient is
87 years, and still has
good cognitive and
functional status. She
has diabetes,
hypertension and
hypercholesterolemia.
Criterion: STOPP-PIP
“Long-term long-
acting
benzodiazepines”.
Context: The patient
has been taking 8mg
prazepam every day
for more than a
month. She has low
fall risk (Tinetti score
26/28b) but she has
cognitive impairment
(MMSE=18/30).
Criterion: STOPP-PIP/
Beers-PIP “Aspirin in
primary
cardiovascular
prevention”.
Context: The patient
has no history of
coronary, cerebral or
peripheral vascular
symptoms or
occlusive event.
Criterion: Beers- PIP
“Tertiary tricyclic
antidepressants”.
Context: The patient is
on clomipramine for
“depressive
tendencies” according
to the GP. The GDS-15
score is low (3/15c).
Non pharmacologic or
safer alternatives are
available.
Minor
clinical
importance
(n = 2)
Modification of the
treatment according to
these criteria brings no
benefit or minor
benefit, depending on
professional
interpretation
Table 4 Clinical importance of potentially inappropriate
prescribing criteria according to the expert panel (Continued)
Criterion: Beers-PIP
“Avoid antiarrhythmic
drugs as first-line
treatment of atrial
fibrillation”.
Context: This patient
receives amiodarone
and does not suffer
from any side effect of
this drug.
Criterion: Beers-PIP
“Avoid long duration
sulfonylurea”.
Context: The patient is
on gliclazide extended
release formula. He is
intolerant to
metformine. No
hypoglycemia were
reported.
Deleterious
clinical
importance
(n = 1)
Modification of the
treatment according to
this may lead to
adverse outcome.
Criterion: START-PIP
“Statin therapy in
diabetes mellitus if
coexisting major
cardiovascular risk
factors present”.
Context: The patient
has a documented
allergy to statins.
Non
applicable
(n = 40)
The criterion is not
applicable to the
individual context of
the patient.
Criterion: START-PIP
“beta-blocker with
chronic stable
angina”.
Context: The patient
had a single episode
of suspected angina in
the past, and he has
asthma.
Criterion: START-PIP
“Aspirin therapy in
diabetes mellitus if
coexisting major
cardiovascular risk
factors present”.
Context: The patient is
already on anti-
vitamin K and he has
no acute coronary
disease.
Criterion: STOPP-PIP
“Any duplicate drug
class prescription”.
Context: The
prescription includes a
patch of nitroglycerin
and tablets of
isosorbide dinitrate.
However, in his notes,
the GP specifies that
the patient uses the
tablets “as needed”
only.
Criterion: STOPP-PIP
“Long-term use of
NSAID for symptom
relief of mild
osteoarthritis”.
Context: The 83 year
old patient has
chronic knee pain
despite the use of
paracetamol.
Unfortunately, his
severe respiratory and
cardiac status is a
contra-indication to
surgery and he is
intolerant to
alternatives to NSAID.
He is on proton-pump
inhibitor.
Criterion: Beers-PIP
“Avoid antipsychotics
in dementia &
cognitive
impairment”.
Context: This patient
has cognitive
impairment but also a
long story of
psychiatric disorders.
Criterion: Beers-PIP
“Avoid
benzodiazepines for
the treatment of
insomnia, agitation, or
delirium”.
Context: This patient
received alprazolam to
improve her sleep in a
context of severe
chronic anxiety.
Abbreviation: GDS-15 geriatric depression scale, GP general practitioner, MMSE
mini mental state examination, NSAID non-steroidal anti-inflammatory drugs,
NYHA New York Heart Association Functional Classification, PIP potentially
inappropriate prescribing
aMMSE<25 was considered as “cognitive impairment”
bTinetti score >24 was considered as “low fall risk”
cGDS-15 score >4 was considered as “possible depression”
Dalleur et al. BMC Geriatrics  (2015) 15:156 Page 6 of 9
In younger patients, STOPP-PIPS have been related to
polypharmacy, age, institutionalisation, and increased co-
morbidity), while START-PIPs were variably related to
age, female gender, and increased comorbidity [1, 13, 40].
Our results confirm the importance of the comorbidity
burden in the risk of having PIPs.
Only a few previous studies looked at the clinical
importance of PIPs detected by explicit tools in patients
[14–16]. Our analysis on the subsample showed the same
trends as previous studies on the Beers list [15, 16] and
STOPP [14]: a substantial proportion of PIPs were actually
appropriate, the relevance varied according to the drug
type and some criteria appeared less controversial than
others (Table 5). Our review of the subsample of patients
reinforces the idea that PIPs are actually only potential
and that solely looking at the criteria is not sufficient to
decide if the prescribing is inappropriate or not. A holistic
approach to the patient challenges the PIPs detected by
explicit screening tools, as illustrated in Table 5.
Strengths and limitations
This study goes one step further than previous observa-
tional studies on PIPs, by providing important findings
about the validity of the use of explicit tools and highlight-
ing how a holistic approach matters when reviewing the
treatment.
This study presents some limitations. The data used to
detect PIPs were not prospectively collected for the
purpose of this analysis. Therefore, the quantity of PIPs
might have been underestimated. For example, PIPs
related to the history of falls, which were frequently
reported in previous studies [41], were infrequent in our
study (likely due to under-reporting of falls as a medical
condition by GPs). However, we observed that a fifth of
the patients on benzodiazepines were at high fall risk.
Criteria related to delirium and dementia were expected
to be infrequently encountered because these patients
were excluded from the cohort.
The analysis on the clinical relevance of the criteria
was only performed on a small subsample of PIPs. This
assessment was designed to provide an insight but did
not intend to comprehensively evaluate the content of
the full criteria lists. Further studies should assess the
actual inappropriateness of all the drugs listed on the
tools in larger extent. However, this subsample allowed
to discuss the most frequent PIPs and enabled us to
identify several important points for discussion on the
validity of the tools.
Implications for research and/or practice
Based on this analysis, including the examples detailed
in Table 5, we suggest some important modifications to
the tools to improve their validity and applicability
(Table 6). The main suggestion for the future use of
screening tools in daily practice is that these tools can
only be used in addition of an assessment of actual ap-
propriateness of prescribing by clinicians with a good
understanding of the patient global health situation and
full access to the patient’s history. In many ways, the GP
appears as the foremost potential user of the tools. In-
deed, the GP knows the patient the best, thanks to a
long relationship and global vision of the patient
Table 5 How a holistic approach of the patient challenges the
PIPs detected by explicit screening tools
Elements of the patient’s record that influence the applicability of the
criteriaa
• Level of severity of a disease
• Certainty of the diagnoses
• Timing of the medical history (recent event vs. long ago)
• Actual intake of the drug that differs from the prescription
• Patient’s preferences and objectives
• Mental status of the patient and associated psychiatric conditions
• Absence of alternative treatment
• Patient’s pain status
• Drug-drug interactions
• Risk factors for bleeding or for stroke
• Contra-indication
• Allergies
Situations that question the content validity of the criteria:
• START-PIP in patients already treated by suitable alternative medica-
tions e.g., “Proton pump inhibitor with severe gastroesophageal acid re-
flux disease” in a patient already on histamine H2-receptor
antagonist.
• START-PIP “Warfarin in the presence of chronic atrial fibrillation”
in patients with low stroke risk
• START-PIP “Regular inhaled β2-agonist or anticholinergic agent for
mild-to-moderate asthma or COPD” in a patient with asthma due to
acid reflux
• STOPP-PIP “Any duplicate drug class prescription” because insufficiently
defined.
• Beers-PIPs mentioning that a medication should be avoided as
“first-line therapy” because such a feature is often difficult to detect
• Beers-PIP “Avoid antidepressants in dementia & cognitive impairment”
in a patient with severe depression
aSee examples in Table 4
Table 6 Recommendations to improve the validity and applicability of explicit tools
Recommendations to improve the
validity of the criteria
Recommendations to improve the
applicability of the criteria
• mention of contra-indications of the criteria
• no contradictions between criteria
• no overlap between criteria
• precise range of application of the criteria
(inclusion criteria)
• mention of time to benefit [45, 46]
• clear definitions (conditions, diseases, drug categories)
• monitoring tips
• suggestions of alternatives (pharmacological and
non-pharmacological)
• mention of adaptation to functional and cognitive status,
life-expectancy, and multimorbidity.
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medical, social and functional status. Very recently, an
updated version of the STOPP&START tool was pub-
lished [42]. Some of the criteria for which the validity
was questioned in our study have been removed. How-
ever, we believe that most recommendations in Table 6
remain valid. Moreover, the message about the para-
mount importance of using the tools as part of a holistic
approach is applicable to any explicit criteria list.
Our results therefore somewhat question the applica-
tion of explicit screening tools to administrative data-
bases. This approach, which was regularly performed in
previous studies [34, 43], is valuable to have a global
insight into PIPs patterns and the most frequently en-
countered drugs. But the prevalence and frequencies
should be interpreted with caution. Issues identified can
only be deemed potentially inappropriate owing to the
limited clinical information available in such databases.
Application of explicit tools to large databases should be
refined so as to take into account factors that decrease
applicability of some criteria (e.g., contra-indications or
presence of alternative drugs for START criteria).
Perspectives for future research are provided by this
baseline analysis of the BELFRAIL cohort. Longitudinal
analysis should compare the incidence of geriatric ad-
verse events (death, hospital admissions, falls, adverse
drug events) and costs of care in patients having or not
confirmed PIPs at baseline. Additional qualitative re-
search could enlighten some of the barriers to imple-
ment screening tools. Furthermore, the viewpoint of the
patient on the appropriateness of his own treatment
should be explored.
Conclusions
Our observations highlight the high prevalence of PIPs
in very old patients in primary care. The medication
review should be part of a comprehensive process to
optimize pharmacotherapy. Explicit tools help to revise
the treatment but will never replace good clinical judge-
ment [44]. The general practitioner plays a key-role in
the management of chronic drug treatment and is there-
fore potentially in the best position to collaborate and to
apply the explicit tool. A good understanding of the
patients’ medical, functional and social context is crucial
to assess the actual appropriateness of drug treatment.
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